Navigating New Data in the Breast Cancer Treatment Paradigm | Supplements and Featured Publications

November 06, 2024

Aditya Bardia, MD, MPH, FASCO, discusses QOL outcomes among patients with HER2-low and HER2-ultralow breast cancer from the DESTINY-Breast06 trial.

November 05, 2024

Kevin Kalinsky, MD, MS, discusses future treatment directions with T-DXd in breast cancer, as well as the evolving role of HER2 classification.

September 15, 2024

T-DXd improved time to deterioration for pain and other subscores, with no decline in overall QOL in HER2 low/ultralow breast cancer.

September 14, 2024

Nancy U. Lin, MD, discusses the DESTINY-Breast12 trial of T-DXd in patients with HER2-positive metastatic breast cancer with or without brain metastases.

September 13, 2024

T-DXd showcased overall and intracranial activity in patients with HER2-positive metastatic breast cancer with stable and active brain metastases.

June 20, 2024

DESTINY-Breast03 and DESTINY-Breast06 showed that T-DXd is a beneficial treatment approach in HER2-positive, -low, and -ultralow metastatic breast cancer.

June 19, 2024

Paolo Tarantino, MD, discusses updated data from the phase 3 DESTINY-Breast03 trial of trastuzumab deruxtecan in HER2-positive breast cancer.

June 13, 2024

VK Gadi, MD, PhD, discusses findings from the DESTINY-Breast06 trial and the implications for hormone receptor–positive, HER2-low metastatic breast cancer.

June 07, 2024

VK Gadi, MD, PhD, discusses primary results from the phase 3 DESTINY-Breast06 trial of trastuzumab deruxtecan in HR-positive, HER2-low breast cancer.

June 07, 2024

Mark Pegram, MD, discusses implications of and safety data from the primary analysis of the DESTINY-Breast06 trial in HR+/HER2– metastatic breast cancer.